<DOC>
	<DOC>NCT02639351</DOC>
	<brief_summary>Dosage-Escalation Study to Evaluate the Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine in Healthy Adults (18-45 years of age).</brief_summary>
	<brief_title>Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>1. Male or female individuals of 18 through 45 years of age on the day of informed consent 2. Healthy volunteers with good physical and mental health status, determined on the basis of the medical history, a physical examination and the results of the screening tests as judged by the investigator 3. Individuals who have voluntarily given written informed consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry 4. Individuals who can comply with study procedures including followup 5. Individuals that are able to understand, read and write German language 6. Females of childbearing potential who are using an effective birth control method which they intend to use for at least 30 days after the study vaccination. 1. Progressive, unstable or uncontrolled clinical conditions 2. Hypersensitivity, including allergy, to any component of vaccines, medicinal products or medical equipment whose use is foreseen in this study 3. Clinical conditions representing a contraindication to intramuscular vaccination and blood draws 4. Abnormal function of the immune system 5. Received immunoglobulins or any blood products within 180 days prior to informed consent 6. Received an investigational or nonregistered medicinal product within 30 days prior to informed consent or intend to participate in another clinical study at any time during the conduct of this study 7. Vulnerable subjects (e.g. persons kept in detention), study personnel or an immediate family or household member of study personnel, subjects with legal incapacity or limited legal capacity 8. Any relevant deviation from the laboratory parameters at screening as judged by the investigator 9. Previously received any vaccine that included a MenC antigen 10. Previously suspected or confirmed disease caused by N. meningitides 11. Had household contact with and/or intimate exposure to an individual with culture proven MenC 12. A positive serum or urine pregnancy test prior to the study vaccine administration or are currently lactating. 13. A positive drugsofabuse test prior to the study vaccine administration; 14. Received any other vaccines within 30 days prior to enrolment in this study or who are planning to receive any vaccine within 30 days from the administration of study vaccines 15. Any other condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subject due to participation in the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>